Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

iEnvision

- PMLiVE

Merck strengthens KRAS stake with Taiho and Astex partnership

Partner companies could gain $2.5bn in milestone payments

- PMLiVE

Envision Pharma Group announces changes in its executive team

Current CEO Brian Hepburn will be succeeded by CCO David Thompson

- PMLiVE

Otsuka presses on with Alzheimer’s agitation drug

Surprise announcement comes on the heels of phase 3 trial fail

- PMLiVE

Avanir’s week goes from bad to worse with Alzheimer’s stumble

Suffers a blow as second phase 3 trial misses the mark

- PMLiVE

Envision Pharma Group relocates to support expansion

Office moves in the US prompted by significant growth

- PMLiVE

Envision appoints new patient partnerships leader

Joins from Cancer Research UK

- PMLiVE

Verily unveils next-gen trials alliance with Novartis, Pfizer

New data methods and tech will be used to streamline trials

- PMLiVE

Otsuka’s Alzheimer’s agitation drug hits the mark

Drug addresses one of the most challenging symptoms in dementia care

- PMLiVE

Envision Pharma Group relocates to support growth

Expands its Horsham to accommodate for additional team members

- PMLiVE

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

The latest from pharma, biotech and healthcare

- PMLiVE

Otsuka utilises Envision Pharma Group’s medical affairs platform

The programme offers Otsuka’s stakeholders a more “user friendly” experience

- PMLiVE

Otsuka finally gets FDA OK for kidney disease drug

Approval at last for rare disease treatment

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links